CYTOTOXIC AGENT FOR CHEMICAL DISBUDDING AND METHOD [0001] RELATED APPLICATIONS [0002] This application claims priority of Australian Provisional Patent Application No. 2022902548, filed 5 September 2022, the entire contents of which are incorporated herein by reference. [0003] TECHNICAL FIELD [0004] This invention broadly relates to a cytotoxic agent and its use in animal disbudding or for inhibiting horn growth in a juvenile animal. In particular, the cytotoxic agent is a non-steroidal anti- inflammatory drug (NSAID) such as meloxicam or ketoprofen. [0005] BACKGROUND [0006] Horn disbudding is a routine husbandry practice in most dairy herds around the world. Disbudding is a procedure in which the horn buds of a calf are removed or destroyed with the use of a thermal cautery (hot iron) unit to burn and destroy the tissue around the horn bud. The hot iron equipment used for disbudding is potentially hazardous due to the use of high temperatures. Successful disbudding requires experience and skill, while improper technique can lead to injuries to the animal and operator. [0007] Even when administered correctly, a hot iron disbudding procedure will cause pain and distress to the animal if performed without appropriate anaesthesia and analgesia. In New Zealand, it is illegal to disbud a calf unless it is “under the influence of an appropriately placed and effective local anaesthetic” (Animal Welfare (Care and Procedures) Regulations 2018). The ideal welfare protocol for disbudding includes administration of a sedative to reduce the stress during the procedure, injection of local anaesthetic to the corneal nerve to anaesthetise the horn buds and surrounding tissue, and administration of an NSAID to reduce post-operative pain. However, the combination of these procedures is still not guaranteed to provide a comfortable experience for the animal. The cost and availability of the appropriate drugs to the animal handlers are hurdles in most countries. The recommended treatment as above also requires experience and skill in administering the proper drug regime. In particular, correctly administering an anaesthetic to the corneal nerve requires training on the proper procedure. [0008] Other less common methods of disbudding include directly cutting out the horn bud with a scoop or gouge, and chemical disbudding using caustic soda. Removal of horn buds by cutting has been observed to cause more pain and distress than the use of a hot iron and leaves a large, open wound. [0009] There are reports in literature of experimental methods of disbudding that have been trialled. A paper in 1976 (Koger LM. Dehorning by injection of calcium chloride. Vet Med Small Anim Clin 1976;71(6):824-825) describes a method in which high concentrations of calcium chloride were injected into the horn bud, causing necrosis of the tissue. This method also caused significant inflammation and would be expected to cause considerable pain. The authors recommended the use of analgesics and sedatives. [0010] The use of caustic soda has been trialled. Caustic soda often inadvertently spreads from the administration site to other areas of the animal and other animals through contact, can lead to blindness of the treated animals and is adversely affected by rain. [0011] The use of liquid nitrogen as a cryogenic fluid to destroy the horn bud tissue has been attempted, but found to be almost entirely ineffective. [0012] The injection of clove oil (eugenol) under the horn bud to cause necrosis of horn-bud tissue has been trialled, but was found to be relatively ineffective, delaying rather preventing horn growth in many cases, and was not recommended by the original investigators (Sutherland et al Vet Sci. 2019 Dec; 6(4): 102). [0013] Consequentially, there is a need for an improved composition or method for preventing the growth of horns in juvenile animals. [0014] OBJECT OF THE INVENTION [0015] It is an object of one or more embodiments of the present invention to address one or more of the foregoing problems. Alternatively, it is an object of one or more embodiments of the present invention to provide a composition for, or method of, chemical disbudding that overcomes or minimises a disadvantage of known dehorning compositions or methods referred to above. Alternatively, it is an object of the present invention to provide the public with a useful choice. [0016] DETAILED DESCRIPTION OF THE INVENTION [0017] The invention broadly relates to a cytotoxic agent and its use in animal disbudding. [0018] According to a first aspect of the present invention, there is provided a method of chemically disbudding a juvenile animal by administering to horn bud cells of the animal at least one cytotoxic agent, wherein the at least one cytotoxic agent comprises at least one non-steroidal anti-inflammatory drug (NSAID). [0019] According to a second aspect of the present invention, there is provided use of at least one cytotoxic agent for chemically disbudding a juvenile animal, wherein the at least one cytotoxic agent comprises at least one non-steroidal anti-inflammatory drug (NSAID). [0020] According to a third aspect of the present invention, there is provided at least one cytotoxic agent for use or when used for chemically disbudding a juvenile animal, wherein the at least one cytotoxic agent comprises at least one non-steroidal anti-inflammatory drug (NSAID). [0021] According to a fourth aspect of the present invention, there is provided use of at least one cytotoxic agent in the manufacture of a medicament for chemically disbudding a juvenile animal, wherein the at least one cytotoxic agent comprises at least one non-steroidal anti-inflammatory drug (NSAID). [0022] According to a fifth aspect of the present invention, there is provided a disbudding composition comprising at least one cytotoxic agent, formulated for administration to and for chemically disbudding a juvenile animal, wherein the at least one cytotoxic agent comprises at least one non-steroidal anti-inflammatory drug (NSAID). [0023] According to a sixth aspect of the present invention, there is provided a method of inhibiting horn growth in a juvenile animal by administering to horn bud cells of the animal at least one cytotoxic agent, wherein the at least one cytotoxic agent comprises at least one non-steroidal anti-inflammatory drug (NSAID). [0024] According to a seventh aspect of the present invention, there is provided use of at least one cytotoxic agent for inhibiting horn growth in a juvenile animal, wherein the at least one cytotoxic agent comprises at least one non-steroidal anti-inflammatory drug (NSAID). [0025] According to an eighth aspect of the present invention, there is provided at least one cytotoxic agent for use or when used for inhibiting horn growth a juvenile animal, wherein the at least one cytotoxic agent comprises at least one non-steroidal anti-inflammatory drug (NSAID). [0026] According to a ninth aspect of the present invention, there is provided use of at least one cytotoxic agent in the manufacture of a medicament for inhibiting horn growth in a juvenile animal, wherein the at least one cytotoxic agent comprises at least one non-steroidal anti-inflammatory drug (NSAID). [0027] According to a tenth aspect of the present invention, there is provided a composition comprising at least one cytotoxic agent, formulated for administration to and for inhibiting horn growth in a juvenile animal, wherein the at least one cytotoxic agent comprises at least one non- steroidal anti-inflammatory drug (NSAID). [0028] According to an eleventh aspect of the present invention, there is provided an injector containing at least one cytotoxic agent for use or when used for juvenile animal disbudding or for inhibiting horn growth in a juvenile animal, wherein the injector is capable of administering the at least one cytotoxic agent to horn bud cells of a juvenile animal, wherein the at least one cytotoxic agent comprises at least one non-steroidal anti-inflammatory drug (NSAID). [0029] According to a twelfth aspect of the present invention, there is provided a kitset for use or when used in a method of juvenile animal disbudding or inhibiting horn growth in a juvenile animal, wherein the kitset comprises: an injector capable of administering at least one cytotoxic agent to horn bud cells of a juvenile animal; and, the at least one cytotoxic agent in an amount to kill horn bud cells, wherein the at least one cytotoxic agent comprises at least one non-steroidal anti- inflammatory drug (NSAID). [0030] According to a thirteenth aspect of the present invention, there is provided a composition formulated as a solution, suspension, dispersion, emulsion, low viscosity gel, or other prolonged- release liquid formulation, comprising at least one cytotoxic agent and one or more excipients, and being capable of providing prolonged-release of the at least one cytotoxic agent, wherein the at least one cytotoxic agent comprises at least one NSAID. [0031] It is to be appreciated that features recited for a particular aspect of the present invention may be features, or recast as features, of any and all other aspects of the present invention, context permitting. For example, one or more features of a ‘method’ (method, use, process etc.) may be recast as features of a ‘product’ (cytotoxic agent, composition, medicament, formulation, injector, kitset etc.), and vice-versa, context permitting. [0032] A ‘cytotoxic agent’ refers to an agent that is toxic to horn bud cells, particularly corium, which can be destroyed and/or inactivated by the cytotoxic agent. [0033] The term ‘at least one cytotoxic agent’, context permitting, is to be interpreted as meaning 1, 2, 3 or more cytotoxic agents. [0034] The term ‘the at least one cytotoxic agent comprises at least one NSAID’, context permitting, is to be interpreted as meaning that the at least one cytotoxic agent can comprise 1, 2, 3 or more NSAIDs. [0035] Although not always explicitly stated, it is to be appreciated that the NSAID cytotoxic agent will typically be administered to the animal in the form of a composition, formulation or medicament. [0036] It is to be appreciated that disbudding or inhibition of horn growth can be achieved by administering the cytotoxic agent directly to horn bud cells (horn bud tissue) of the animal, or in an immediate vicinity of horn bud cells. Preferably, disbudding or horn inhibition is carried out whilst the horn bud is free-floating in the skin. Preferably disbudding or horn inhibition is carried out before the horn bud has attached to the skull. Preferably the cytotoxic agent is administered under or around the horn buds, more preferably under the horn buds. Successful disbudding or horn inhibition requires inactivation or destruction of horn-producing cells (corium) (ie. ‘horn bud cells’) of the horn bud. [0037] Preferably the cytotoxic agent is administered in an amount (ie. an ‘effective amount’) sufficient to prevent horn growth, or significantly reduce horn growth such that the resulting horn/scur/stump/bud is not of danger to other animals. Preferably horn growth is prevented completely. [0038] The cytotoxic agent can be administered as a single dose or more than one dose, but preferably as a single dose. [0039] Any suitable NSAID can be used as the cytotoxic agent. In some embodiments, the NSAID cytotoxic agent can be in a free-acid or free-base form, or a salt. Context permitting, the terms ‘cytotoxic agent’ and ‘NSAID’ include the free-acid or free-base form of the cytotoxic agent and NSAID as well as any salt or salts of that cytotoxic agent or NSAID. In some instances, one or more salts of a cytotoxic agent or NSAID may be specifically mentioned for greater clarity. [0040] Potentially suitable NSAIDs include: indazoles such as benzydamine, salicylates (e.g., aspirin (acetylsalicylic acid), diflunisal (dolobide), salicylic acid and other salicylates, salsalates (salsalate)), propionic acid derivatives (e.g., ibuprofen, dexibuprofen, naproxen, fenoprofen, ketoprofen, dexketoprofen, flurbiprofen, oxaprozin, loxoprofen), acetic acid derivatives (e.g., indomethacin, tolmetin, sulindac, etodolac, ketorolac, diclofenac, aceclofenac, nabumetone), alkenoic acid (oxicam) derivatives (e.g., piroxicam, meloxicam, tenoxicam, trioxicam, lornoxicam, isoxicam, phenylbutazone), anthranilic acid derivatives (fenamic acid) (e.g., mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid), selective COX-2 inhibitors (e.g., lenebutyric acid, valacic, flufenamic acid, tolfenamic acid), and the like, Rofecoxib, Varcoxib, Celecoxib, Parecoxib, Lumiracoxib, Etacoxib, Filocoxib), sulfonamides (e.g., nimesulide) or other drugs (e.g., lonicin, lincomron, H-harpagide in figwort or devil's claw). [0041] In some embodiments, the NSAID is aspirin (acetylsalicylic acid), phenylbutazone, meclofenamic acid, tolfenamic acid, flunixin, carprofen, ketoprofen, etodolac, vedaprofen, meloxicam, deracoxib, firocoxib, robenacoxib, mavacoxib, grapiprant, benzydamine, or dipyrone. Preferably, meloxicam (C ₁₄ H ₁₃ N ₃ O ₄ S ₂ ) or ketoprofen (2-(3-Benzoylphenyl)propanoic acid) is used as the NSAID cytotoxic agent. [0042] For all aspects of the present invention, preferably the NSAID is meloxicam or ketoprofen. [0043] The animal can be any type of animal that can develop true horns from horn buds. Such animals include, but are not limited to, bovine animals (cow or bull), goats, sheep, bison, African buffalo, gazelles, muskoxen and antelope. Preferably, the juvenile animal is a calf or a kid. [0044] Any suitable quantity of cytotoxic agent (or cytotoxic agents) can be used, provided that it is cytotoxic to horn bud cells. The quantity administered depends on the potency of the cytotoxic agent, and the size or volume of the horn bud area. The quantity of cytotoxic agent administered to horn bud cells is preferably in the range of approximately 5 to 1000 mg, including all numerical values and subranges between 5 and 1000. More preferably, the quantity of cytotoxic agent administered to horn bud cells is in the range of approximately 5 to 500 mg, including all numerical values and subranges between 5 to 500. [0045] For meloxicam, in some embodiments approximately 5 to 500 mg is administered, preferably approximately 5 to 250 mg, more preferably approximately 20 to 200 mg, more preferably approximately 20 to 150 mg, and most preferably approximately 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 mg (including all numerical values and subranges between 5 and 500, 20 and 200, and 20 and 150). [0046] For ketoprofen, in some embodiments approximately 50 to 800 mg is administered, preferably approximately 100 to 400 mg, more preferably approximately 120 to 300 mg, more preferably approximately 150 to 300 mg, more preferably approximately 150 to 250 mg, and most preferably approximately 150 mg or 200 mg or 250 mg (including all numerical values and subranges between 50 and 800, 100 and 400, 120 to 300, 150 to 300, and 150 to 250). [0047] Typically, the cytotoxic agent will be administered to the animal in the form of a composition, formulation or medicament suitable for injection. A preferred composition, formulation or medicament is a liquid composition. A preferred composition, formulation or medicament is a prolonged-release composition. Preferred liquid compositions include solutions, suspensions, dispersions, emulsions, and low viscosity gels. Preferred liquid compositions include prolonged-release formulations formulated as solutions, suspensions, dispersions, emulsions, low viscosity gels, and other prolonged-release formulations. [0048] A preferred composition (formulation or medicament) for administration is a liquid composition, suitable for injection. Compositions for injection can be prepared by dissolving or mixing the cytotoxic agent in a suitable veterinary acceptable vehicle, carrier, solvent or excipient etc. which can include further ingredients such as a solubiliser, acid, base, buffer salt, anti- oxidant, and/or preservative. The compositions can be sterilised, such as by heat, filtration or irradiation, or prepared aseptically. Compositions for injection may be prepared by methods and techniques known to persons skilled in the art. [0049] The composition (formulation or medicament) can include one or more of the following types of veterinary acceptable ingredients: a vehicle; an aqueous or oily diluent; a carrier; an excipient; a base; a buffering agent; a pH adjusting agent; a suspending agent; a flocculating agent; a thickener; a viscosity building agent; a gelling agent; a solvent; a co-solvent; a solvent system; an emulsifier; a stabilizer; a dispersant; a solubilizer; a fragrance; a preservative; a surfactant; a detergent, a complexing agent; an acid; a base; an anti-oxidant; a wetting agent; a chelating agent; a reducing agent; a bulking agent; a protectant; a tonicity adjustor; and, a colorant. [0050] Examples of tonicity adjustors used in liquid injections include electrolytes, dextrose, glycerol, sodium chloride, glycerin and mannitol. [0051] Examples of preservatives used in liquid injections include antioxidants, antimicrobials and chelating agents, including ascorbic acid, acetylcysteine, sulfurous acid salts (bisulfite, metabisulfite), monothioglyercol, phenol, meta-cresol, benzyl alcohol, parabens (methyl, propyl, butyl), benzalkonium chloride, chlorobutanol, thiomersal, phenylmercuric salts, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), and alpha tocopherol. [0052] Examples of solubilising agents used in liquid injections include surfactants, solvents and co-solvents, and include water, polyoxyethylene sorbitan monooleate (Tween 80), EDTA, sorbitan monooleate (Span 80), polyoxyethylene sorbitan monolaurate (Tween 20), lecithin, polyoxyethylene copolymers (pluronics), propylene glycol, glycerin, ethanol, polyethylene glycol (300 and 400), sorbitol, dimethylacetamide and cremophor EL. [0053] Examples of complexing and dispersing agents used in liquid injections include cyclodextrins and modified cyclodextrins such as hydroxypropyl-b-cyclodextrin and sulfobutylether- b -cyclodextrin. [0054] Examples of buffering agents used in liquid injections include phosphate, citrate, acetate, lactate and tartrate buffers. [0055] Suspensions, including aqueous or oily suspensions, may provide more prolonged release of the cytotoxic agent from the injection site than a comparable solution. Examples of excipients used in suspensions include flocculating / suspending agents, viscosity building agents, wetting agents, solvent systems, stabilizing agents, preservatives, antioxidants, chelating agents, buffering agents, and tonicity adjusting agents. Examples of excipients or oily suspending agents used in oily suspensions include oils, preferably vegetable oils, such as castor, cottonseed, soybean, ethyl oleate, olive, peanut, sesame, sunflower, soybean and safflower oil. [0056] Examples of flocculating / suspending agents include electrolytes, surfactant and hydrophilic colloids, including potassium/sodium chloride, potassium/sodium citrate, and potassium/sodium acetate. [0057] Examples of viscosity building agents include sodium carboxymethyl cellulose, acacia, gelatin, methyl cellulose, and polyvinyl pyrrolidone. [0058] Examples of wetting agents include glycerin, alcohol, propylene glycol, lecithin, polysorbate 20, polysorbate 80, pluronic F-68, sorbitan trioleate. [0059] Examples of solvents include water, ethanol, glycerin, propylene glycol, n–lactamide, and polyethylene glycol (PEG). [0060] Examples of stabilizers / stabilizing agents include sodium carboxymethyl cellulose, acacia, gelatin, methyl cellulose, polyvinyl pyrrolidone, polymers, PEG and Sucrose Acetate Isobutyrate (SAIB). For example, a supersaturated solution of ketoprofen may include as an excipient a stabilizer such as SAIB, which could prevent or slow ketoprofen from falling out of solution. [0061] In some embodiments the composition (formulation or medicament) is in the form of a low viscosity, injectable gel which gels rapidly at the injection site to retain the cytotoxic agent for a suitable period of time. In this way a larger quantity of cytotoxic agent can be delivered to the horn bud cells (horn bud tissue). [0062] The composition can be made to gel in situ in any suitable way. In some embodiments, the composition comprises one or more gelling agents. In some embodiments, the composition comprises a solvent system. In some embodiments, the composition comprises Sucrose Acetate Isobutyrate (SAIB) and a solvent. Once a composition containing SAIB formulation and solvent is injected, the solvent can diffuse out leaving a matrix that is both adhesive and viscous. The matrix can retain the cytotoxic agent at the horn bud cells for a period of time, rather than the cytotoxic agent dispersing immediately. [0063] The SAIB may have a molecular weight of 846.9 (CAS number 27216-37-1 or 126-13-6). [0064] In some embodiments, the composition comprises approximately: 30% to 90% w/v SAIB; 30% to 80% w/v SAIB; 30% to 70% w/v SAIB; 30% to 60% w/v SAIB; 30% to 50% w/v SAIB; 30% to 40% w/v SAIB; 40% to 90% w/v SAIB; 40% to 80% w/v SAIB; 40% to 70% w/v SAIB; 40% to 60% w/v SAIB; 40% to 50% w/v SAIB; 50% to 90% w/v SAIB; 50% to 80% w/v SAIB; 50% to 70% w/v SAIB; 50% to 60% w/v SAIB; 60% to 90% w/v SAIB; 60% to 80% w/v SAIB; 60% to 70% w/v SAIB; 70% to 90% w/v SAIB; 70% to 80% w/v SAIB; 80% to 90% w/v SAIB; 50% w/v SAIB; 55% w/v SAIB; 60% w/v SAIB; 65% w/v SAIB; 70% w/v SAIB; 75% w/v SAIB; 80% w/v SAIB; 85% w/v SAIB; or, 90% w/v SAIB. These ranges include all possible subranges and numerical values between each upper and lower numerical value, and include each numerical value between 30 and 90, including 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 86, 86, 87, 88, 89 and 90. [0065] In some embodiments, the composition comprises, as an injectable / administrable dose, approximately 65% w/v SAIB and approximately 250 mg ketoprofen, with one or more solvents. In some embodiments, the composition comprises approximately 50% w/v SAIB and approximately 350 mg ketoprofen, with one or more solvents. In some embodiments, the composition comprises approximately 70-80% w/v SAIB with approximately 120 mg to 250 mg ketoprofen, with one or more solvents. [0066] Any suitable solvent or solvents can be used provided that they produce a low viscosity, injectable gel. Preferred solvents include ethanol, diethylene glycol monoethyl ether (DEGEE) sold under the trade mark Transcutol, N-methylpyrrolidone (NMP), triacetin, benzyl benzoate, miglyol, propylene carbonate, benzyl alcohol, ethyl lactate, glycofurol, 2-pyrrolidone, propylene glycol, acetone, methyl acetate, ethyl acetate, methyl ethyl ketone, dimethylformamide, dimethylsulfoxide, tetrahydrofuran, caprolactam, decylmethylsulfoxide, oleic acid, and 1- dodecyazacycloheptan-2-one. Preferably, ethanol is used. The solvent can be present in an amount of between approximately 5–50% w/v, preferably approximately 10–50% w/v, and more preferably approximately 15-30% w/v. These ranges include all numerical values and subranges between 5 and 50, 10 and 50, and 15 and 30. Preferably an ethanol content of at least 10% w/v ethanol is used. [0067] The concentration of cytotoxic agent in a composition administered to an animal is preferably in the range of approximately 0.01% weight/volume (w/v) to nearly approximately 100% w/v, depending on the potency of the cytotoxic agent, including all numerical values between 0.01 and 100 including approximately 0.01, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 86, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100. [0068] The volume of composition administered to a horn bud is preferably within the range of approximately 0.05 to approximately 10 mL, including all numerical values between 0.05 and 10. A particularly preferred range is from approximately 0.1 to 1.0 mL, including all numerical values between 0.1 and 1. For example, a composition quantity of approximately 0.3 mL, 0.4 mL, 0.5 mL, 0.6 mL, 0.7 mL, 0.8 mL, 0.9 mL or 1.0 mL can be administered to a horn bud. Preferably up to approximately 1 mL of composition is administered. However, in some cases up to approximately 1.5 mL can be administered, including approximately 1.1, 1.2, 1.3, 1.4 and 1.5 mL. [0069] The cytotoxic agent can be administered to the juvenile animal in any suitable way. Preferably, the cytotoxic agent is administered by injection. In some embodiments a single injection is administered. In some embodiments, more than one injection is administered, such as 2, 3 or 4 injections over a suitable period of time. [0070] Preferably an injector is used to carry out injection of (administration to) the animal. Preferably an injector suitable for single-handed use is used, so as to allow use of the other hand to steady the animal’s head and locate the horn bud. [0071] In some embodiments, the injector is suitable for providing multiple doses, such as an automatic vaccinator injector, a self-refilling injection syringe, or a multi-dose automatic syringe. One example of a suitable injector is the McLintock syringe, conventionally used for tuberculin testing, but can be configured to administer the required dosage volume. [0072] Preferred embodiments of the invention are defined in the numbered paragraphs below: [0073] 1. A method of chemically disbudding a juvenile animal or inhibiting horn growth in a juvenile animal by administering to horn bud cells of the animal at least one cytotoxic agent, wherein the at least one cytotoxic agent comprises at least one non-steroidal anti-inflammatory drug (NSAID). [0074] 2. Use of at least one cytotoxic agent for chemically disbudding a juvenile animal or inhibiting horn growth in a juvenile animal, wherein the at least one cytotoxic agent comprises at least one NSAID. [0075] 3. At least one cytotoxic agent for use or when used for chemically disbudding a juvenile animal or inhibiting horn growth in a juvenile animal, wherein the at least one cytotoxic agent comprises at least one NSAID. [0076] 4. Use of at least one cytotoxic agent in the manufacture of a medicament for administration to and chemically disbudding a juvenile animal or inhibiting horn growth in a juvenile animal, wherein the at least one cytotoxic agent comprises at least one NSAID. [0077] 5. A composition comprising at least one cytotoxic agent, formulated for administration to and for chemically disbudding a juvenile animal or inhibiting horn growth in a juvenile animal, wherein the at least one cytotoxic agent comprises at least one NSAID. [0078] 6. An injector containing at least one cytotoxic agent for use or when used for juvenile animal disbudding or for inhibiting horn growth in a juvenile animal, wherein the injector is capable of administering the at least one cytotoxic agent to horn bud cells of a juvenile animal, wherein the at least one cytotoxic agent comprises at least one NSAID. [0079] 7. A kitset for use or when used in a method of juvenile animal disbudding or inhibiting horn growth in a juvenile animal, wherein the kitset comprises: an injector capable of administering at least one cytotoxic agent to horn bud cells of a juvenile animal; and, the at least one cytotoxic agent in an amount to kill horn bud cells, wherein the at least one cytotoxic agent comprises at least one NSAID. [0080] 8. The method of paragraph 1, the use of paragraph 2, the at least one cytotoxic agent for use or when used in accordance with paragraph 3, the use according to paragraph 4, the composition of paragraph 5, the injector of paragraph 6, or the kitset of paragraph 7, wherein the at least one cytotoxic agent is in the form of a free-acid, free-base, or salt. [0081] 9. The method of paragraph 1 or 8, the use of paragraph 2 or 8, the at least one cytotoxic agent for use or when used in accordance with paragraph 3 or 8, the use according to paragraph 4 or 8, the composition of paragraph 5 or 8, the injector of paragraph 6 or 8, or the kitset of paragraph 7 or 8, wherein the at least one cytotoxic agent comprises at least one NSAID selected from aspirin (acetylsalicylic acid), phenylbutazone, meclofenamic acid, tolfenamic acid, flunixin, carprofen, ketoprofen, etodolac, vedaprofen, meloxicam, deracoxib, firocoxib, robenacoxib, mavacoxib, grapiprant, benzydamine, and dipyrone. [0082] 10. The method of paragraph 9, the use of paragraph 9, the at least one cytotoxic agent for use or when used in accordance with paragraph 9, the use according to paragraph 9, the composition of paragraph 9, the injector of paragraph 9, or the kitset of paragraph 9, wherein the at least one cytotoxic agent comprises meloxicam or ketoprofen. [0083] 11. The method of paragraph 10, the use of paragraph 10, the at least one cytotoxic agent for use or when used in accordance with paragraph 10, the use according to paragraph 10, the composition of paragraph 10, the injector of paragraph 10, or the kitset of paragraph 10, wherein: [0084] the amount of at least one cytotoxic agent administered or administrable comprises approximately 5 to 500 mg meloxicam, more preferably approximately 20 to 250 mg meloxicam; [0085] the amount of at least one cytotoxic agent administered or administrable comprises approximately 5 to 500 mg meloxicam as a free-acid, more preferably approximately 20 to 250 mg meloxicam; [0086] the amount of at least one cytotoxic agent administered or administrable comprises approximately 5 to 500 mg meloxicam as a salt, more preferably approximately 20 to 250 mg meloxicam; [0087] the amount of at least one cytotoxic agent administered or administrable comprises approximately 5 to 800 mg ketoprofen, more preferably approximately 120 to 350 mg ketoprofen; [0088] the amount of at least one cytotoxic agent administered or administrable comprises approximately 5 to 800 mg ketoprofen as a free-acid, more preferably approximately 120 to 350 mg ketoprofen; or [0089] the amount of at least one cytotoxic agent administered or administrable comprises approximately 5 to 800 mg ketoprofen as a salt, more preferably approximately 120 to 350 mg ketoprofen. [0090] 12. The method of any one of paragraphs 1 and 8 to 11, the use of any one of paragraphs 2 and 8 to 11, the at least one cytotoxic agent for use or when used in accordance with any one of paragraphs 3 and 8 to 11, the use according to any one of paragraphs 4 and 8 to 11, the composition of any one of paragraphs 5 and 8 to 11, the injector of any one of paragraphs 6 and 8 to 11, or the kitset of any one of paragraphs 7 and 8 to 11, wherein the at least one cytotoxic agent is administered or administrable to the juvenile animal by way of one or more injections, preferably as a single injection. [0091] 13. The method of any one of paragraphs 1 and 8 to 12, the use of any one of paragraphs 2 and 8 to 12, the at least one cytotoxic agent for use or when used in accordance with any one of paragraphs 3 and 8 to 12, the use according to any one of paragraphs 4 and 8 to 12, the composition of any one of paragraphs 5 and 8 to 12, the injector of any one of paragraphs 6 and 8 to 12, or the kitset of any one of paragraphs 7 and 8 to 12, wherein the at least one cytotoxic agent is administered or administrable to the juvenile animal in the form of a liquid composition capable of providing prolonged-release of the at least one cytotoxic agent. [0092] 14. The method of paragraph 13, the use of paragraph 13, the at least one cytotoxic agent for use or when used in accordance with paragraph 13, the use of paragraph 13, the composition of paragraph 13, the injector of paragraph 13, or the kitset of paragraph 13, wherein the liquid composition is in the form of a solution, suspension, dispersion, emulsion, or low viscosity gel. [0093] 15. The method of paragraph 14, the use of paragraph 14, the at least one cytotoxic agent for use or when used in accordance with paragraph 14, the use of paragraph 14, the composition of paragraph 14, the injector of paragraph 14, or the kitset of paragraph 14, wherein the liquid composition is in the form of: [0094] an injectable oily solution or suspension, and comprising at least one oily excipient; [0095] an injectable aqueous solution or suspension, and comprising at least one excipient; or [0096] a low viscosity, injectable gel formulated to gel rapidly at an injection site and prolong the release of the cytotoxic agent from the gel. [0097] 16. The method of paragraph 15, the use of paragraph 15, the at least one cytotoxic agent for use or when used in accordance with paragraph 15, the use of paragraph 15, the composition of paragraph 15, the injector of paragraph 15, or the kitset of paragraph 15, wherein the low viscosity, injectable gel comprises one or more gelling agents, one or more solvents or a solvent system, and, optionally, one or more surfactants. [0098] 17. The method of paragraph 16, the use of paragraph 16, the at least one cytotoxic agent for use or when used in accordance with paragraph 16, the use of paragraph 16, the composition of paragraph 16, the injector of paragraph 16, or the kitset of paragraph 16, wherein the low viscosity, injectable gel comprises: [0099] Sucrose Acetate Isobutyrate (SAIB) as the one or more gelling agents and at least one type of solvent; or [0100] SAIB as the one or more gelling agents, at least one type of solvent, and at least one type of surfactant. [0101] 18. The method of paragraph 17, the use of paragraph 17, the at least one cytotoxic agent for use or when used in accordance with paragraph 17, the use of paragraph 17, the composition of paragraph 17, the injector of paragraph 17, or the kitset of paragraph 17, wherein the low viscosity, injectable gel comprises: [0102] approximately 30% to 90% w/v SAIB; [0103] approximately 40% to 80% w/v SAIB; [0104] approximately 70% to 80% w/v SAIB; [0105] approximately 60% to 70% w/v SAIB; or [0106] approximately 50% w/v SAIB. [0107] 19. The method of paragraph 17 or 18, the use of paragraph 17 or 18, the at least one cytotoxic agent for use or when used in accordance with paragraph 17 or 18, the use of paragraph 17 or 18, the composition of paragraph 17 or 18, the injector of paragraph 17 or 18, or the kitset of paragraph 17 or 18, wherein the low viscosity, injectable gel comprises: [0108] approximately 10–50% w/v of the at least one solvent; or [0109] approximately 15-30% w/v of the at least one solvent. [0110] 20. The method of paragraph 19, the use of paragraph 19, the at least one cytotoxic agent for use or when used in accordance with paragraph 19, the use of paragraph 19, the composition of paragraph 19, the injector of paragraph 19, or the kitset of paragraph 19, wherein the at least one solvent comprises one or more of ethanol, diethylene glycol monoethyl ether (DEGEE), N- methylpyrrolidone (NMP), triacetin, benzyl benzoate, miglyol, propylene carbonate, benzyl alcohol, ethyl lactate, glycofurol, 2-pyrrolidone, propylene glycol, acetone, methyl acetate, ethyl acetate, methyl ethyl ketone, dimethylformamide, dimethylsulfoxide, tetrahydrofuran, caprolactam, decylmethylsulfoxide, oleic acid, and 1-dodecyazacycloheptan-2-one. [0111] 21. The method of any one of paragraphs 17 to 20, the use of any one of paragraphs 17 to 20, the at least one cytotoxic agent for use or when used in accordance with any one of paragraphs 17 to 20, the use of any one of paragraphs 17 to 20, the composition of any one of paragraphs 17 to 20, the injector of any one of paragraphs 17 to 20, or the kitset of any one of paragraphs 17 to 20, wherein the low viscosity, injectable gel comprises: [0112] approximately 0-3% w/v of the at least one surfactant; [0113] approximately 0-2% w/v of the at least one surfactant; [0114] approximately 0-1% w/v of the at least one surfactant; [0115] approximately 1-3% w/v of the at least one surfactant; or [0116] approximately 1-2% w/v of the at least one surfactant. [0117] 22. The method of paragraph 21, the use of paragraph 21, the at least one cytotoxic agent for use or when used in accordance with paragraph 21, the use of paragraph 21, the composition of paragraph 21, the injector of paragraph 21, or the kitset of paragraph 21, wherein the at least one surfactant comprises one or more of a non-ionic surfactant, polysorbate, Tween, polyoxyethylene (20) sorbitan monooleate (Tween 80), or, polyoxyethylene (20) sorbitan monolaurate (Tween 20). [0118] 23. The method of any one of paragraphs 17 to 22 when dependent on paragraph 17, the use of any one of paragraphs 17 to 22 when dependent on paragraph 17, the at least one cytotoxic agent for use or when used in accordance with any one of paragraphs 17 to 22 when dependent on paragraph 17, the use of any one of paragraphs 17 to 22 when dependent on paragraph 17, the composition of any one of paragraphs 17 to 22 when dependent on paragraph 17, the injector of any one of paragraphs 17 to 22 when dependent on paragraph 17, or the kitset of any one of paragraphs 17 to 22 when dependent on paragraph 17, wherein the low viscosity, injectable gel comprises an approximate formulation selected from the formulations shown below (all % w/v are approximate): [0121] [0122] [0123] [0124] viscosity gel, or other prolonged-release liquid formulation, comprising at least one cytotoxic agent and one or more excipients, and being capable of providing prolonged-release of the at least one cytotoxic agent, wherein the at least one cytotoxic agent comprises at least one NSAID. [0129] 25. The composition of paragraph 24, formulated as an injectable oily solution or suspension, and comprising at least one oily excipient, or formulated as an injectable aqueous solution or suspension, and comprising at least one excipient. [0130] 26. The composition of paragraph 24, formulated as a low viscosity, injectable gel. [0131] 27. The composition of paragraph 26, formulated to gel rapidly at an injection site of an animal and prolong the release of the cytotoxic agent from the gel. [0132] 28. The composition of paragraph 27, wherein the low viscosity, injectable gel comprises one or more gelling agents, one or more solvents or a solvent system, and, optionally, one or more surfactants. [0133] 29. The composition of paragraph 28, wherein the low viscosity, injectable gel comprises: [0134] Sucrose Acetate Isobutyrate (SAIB) as the one or more gelling agents and at least one type of solvent; or [0135] SAIB as the one or more gelling agents, at least one type of solvent, and at least one type of surfactant. [0136] 30. The composition of paragraph 29, wherein the low viscosity, injectable gel comprises: [0137] approximately 30% to 90% w/v SAIB; [0138] approximately 40% to 80% w/v SAIB; [0139] approximately 70% to 80% w/v SAIB; [0140] approximately 60% to 70% w/v SAIB; or [0141] approximately 50% w/v SAIB. [0142] 31. The composition of paragraph 30, wherein the low viscosity, injectable gel comprises: [0143] approximately 10–50% w/v of the at least one solvent; or [0144] approximately 15-30% w/v of the at least one solvent. [0145] 32. The composition of paragraph 31, wherein the at least one solvent comprises one or more of ethanol, diethylene glycol monoethyl ether (DEGEE), N-methylpyrrolidone (NMP), triacetin, benzyl benzoate, miglyol, propylene carbonate, benzyl alcohol, ethyl lactate, glycofurol, 2-pyrrolidone, propylene glycol, acetone, methyl acetate, ethyl acetate, methyl ethyl ketone, dimethylformamide, dimethylsulfoxide, tetrahydrofuran, caprolactam, decylmethylsulfoxide, oleic acid, and 1-dodecyazacycloheptan-2-one. [0146] 33. The composition of paragraph 32, wherein the low viscosity, injectable gel comprises: [0147] approximately 0-3% w/v of the at least one surfactant; [0148] approximately 0-2% w/v of the at least one surfactant; [0149] approximately 0-1% w/v of the at least one surfactant; [0150] approximately 1-3% w/v of the at least one surfactant; or [0151] approximately 1-2% w/v of the at least one surfactant. [0152] 34. The composition of paragraph 33, wherein the at least one surfactant comprises one or more of a non-ionic surfactant, polysorbate, Tween, polyoxyethylene (20) sorbitan monooleate (Tween 80), or, polyoxyethylene (20) sorbitan monolaurate (Tween 20). [0153] 35. The composition of any one of paragraphs 29 to 34, wherein the composition comprises, as an injectable dose: [0154] approximately 65% w/v SAIB and approximately 250 mg ketoprofen, with at least one type of solvent, and optionally at least one type of surfactant; [0155] approximately 50% w/v SAIB and approximately 350 mg ketoprofen, with at least one type of solvent, and optionally at least one type of surfactant; or [0156] approximately 70-80% w/v SAIB with approximately 120 mg to 250 mg ketoprofen, with at least one type of solvent, and optionally at least one type of surfactant. [0157] 36. The composition of any one of paragraphs 29 to 34, wherein the low viscosity, injectable gel comprises an approximate formulation selected from any one of Formulations 1 to 10 described herein. [0158] 37 The method of paragraph 1, the use of paragraph 2, the at least one cytotoxic agent for use or when used in accordance with paragraph 3, the use according to paragraph 4, the injector of paragraph 6, or the kitset of paragraph 7, wherein the at least one cytotoxic agent is formulated as the composition according to any one of paragraphs 24 to 36. [0159] 38. A composition, medicament or formulation as described herein, including in the Examples and Claims, including any one of the Tables shown herein. [0160] BRIEF DESCRIPTION OF THE FIGURES [0161] Further aspects of the present invention will become apparent from the ensuing description (Examples) which is given by way of example only and with reference to the accompanying figures in which: [0162] Figure 1 – Pictures of calf ID:4, treated with ketoprofen: (a) Overview; (b) Treated horn bud; (c) Untreated horn bud. [0163] Figure 2 – Pictures of calf ID:5, treated with ketoprofen: (a) Overview; (b) Treated horn bud; (c) Untreated horn bud. [0164] Figure 3 – Pictures of calf ID:6, treated with ketoprofen: (a) Overview; (b) Treated horn bud; (c) Untreated horn bud. [0165] Figure 4 – Pictures of calf ID:1, treated with meloxicam: (a) Overview; (b) Treated horn bud; (c) Untreated horn bud. [0166] Figure 5 – Pictures of calf ID:2, treated with meloxicam: (a) Overview; (b) Treated horn bud; (c) Untreated horn bud. [0167] Figure 6 – Picture of calf ID:7, horn bud treated with meloxicam. [0168] Example 1 - Efficacy of injecting registered non-steroidal anti-inflammatory drugs (NSAIDs) into the horn buds of young calves to prevent horn growth [0169] Study objective [0170] The objective of this study was to test if two different cytotoxic agent NSAIDs will prevent horn growth if injected into the horn bud of young dairy calves. The second objective was to assess if the injections caused an acceptable pain response from the calves. [0171] Study design [0172] A randomized controlled trial with an internal negative control was used. Six calves were equally assigned to either one of two treatments. The left horn bud was injected with 1 mL 150 mg/mL ketoprofen or with 1 mL 20 mg/mL meloxicam, whereas the right horn bud was the negative (internal) control. [0173] Materials and methods [0174] Animals [0175] Type: Dairy calves, non-polled [0176] Breed: Friesian X Jersey X [0177] Age: 4 – 10 days [0178] Sex: Female [0179] Animal maintenance and husbandry [0180] Test animals were kept amongst non-test animals in the same age group and kept on a commercial dairy farm using common husbandry practices. [0181] Disposition of animals and products [0182] Treatments were commercially available registered veterinary medicines approved for use in this species. The dose did not exceed the label dose. The approved withholding period for tissue was adhered to. [0183] Test products and dosing [0184] Treatment 1: [0185] 1 mL of ketoprofen 150 mg/mL (Ketomax 15%, AgriHealth Ltd). One mL was injected into the centre of the horn bud after trimming the hair around it. [0186] Treatment 2: [0187] 1 mL of meloxicam 20 mg/mL (Rheumocam 20 mg/ml, Ethical Agents). One mL was injected into the centre of the horn bud after trimming the hair around it. [0188] Clinical results [0189] Table 1 - Treatment assignment and comments [0190] Table 2 - Treatment pain response observation by veterinarian [0191] Table 3 - Pain & discomfort observation 6 hours post-treatment [0192] Table 4 - Pain & discomfort observation 48 hours post-treatment [0193] Table 5 - Horn growth assessment [0194] Discussion [0195] The objective of this study was to assess if NSAIDs could prevent horn growth if injected in the horn bud of young calves. Both treatments were successful in preventing horn growth in some cases and reduce the horn growth in other cases (Table 5). Both ketoprofen and meloxicam show the potential of preventing horn growth up until 33 days after treatment. As these treatments (NSAID compositions) were commercially available formulations, the concentration (and thus the absolute dose) of ketoprofen and meloxicam is relatively low. Based on these results, we expect that a dose response study could give a minimum concentration at which near 100% prevention can be achieved. [0196] The second objective was to assess welfare indicators such as pain or discomfort. Both were conducted by New Zealand registered veterinarians. Most of the discomfort or resistance was observed during the handling and treatment/injection (Table 2) with a few calves showing discomfort or pain during a short time period after treatment (Table 2). Six hours and 48 hours after the treatment no signs of pain or discomfort were observed in any of the calves (Tables 3 and 4). Also, none of the treatments induced any swelling (oedema) at the injection site. Shortly after treatment the depot of injected fluid can be observed at the injection site, but this had completely disappeared at the next observation time point at 6 hours post-treatment. [0197] Conclusions [0198] Injecting an NSAID such as ketoprofen 150 mg/mL (150 mg total dose) or meloxicam 20 mg/mL (20 mg total dose) into the horn bud of young calves can prevent horn growth. A dose determination study can be used to establish the dose at which near 100% prevention can be reached. [0199] It is believed that a composition providing prolonged release of the NSAID from the injection site may provide equal or superior disbudding results. It is believed that a lower amount of NSAID could be used in an injectable prolonged release composition as compared to the ones tested. It is envisaged that the administered composition could be in the form of an injectable low viscosity solution or suspension, such as an oily suspension or oily solution, an aqueous suspension or aqueous solution, or low viscosity, injectable gel (suspension or solution) which gels rapidly at the injection site to retain the NSAID for a suitable period of time. In this way, a comparatively larger quantity of cytotoxic agent can be delivered to the horn bud cells (horn bud tissue). It is believed that a composition containing the cytotoxic agent/NSAID, Sucrose Acetate Isobutyrate (SAIB) and a solvent could achieve this. Once the composition containing SAIB formulation and solvent is injected, the solvent can diffuse out leaving a matrix that is both adhesive and viscous. The matrix can retain the NSAID/cytotoxic agent at the horn bud cells for a period of time, rather than the cytotoxic agent being cleared rapidly from the horn bud site. Also, if the composition provides slow clearance of the NSAID from the horn bud site, then a high dose of NSAID could also be administered safely since high concentrations of the NSAID in blood would be avoided. [0200] It is also concluded that both treatments cause negligible pain, discomfort or swelling (oedema) – if at all - after treatment. Most discomfort was caused by handling the animals and the actual injection. [0201] General conclusions [0202] The present inventors have found that NSAIDs such as meloxicam and ketoprofen function as effective chemical disbudding agents, and thereby overcome or reduce many of the disadvantages of previously known disbudding procedures. [0203] Injection of these chemical disbudding agents seems to be well tolerated by animals. [0204] Administration of these chemical disbudding agents is safer and easier compared with conventional dehorning techniques. [0205] Single injection of these chemical disbudding agents can dehorn animals. [0206] These chemical disbudding agents are targeted to horn bud cells/horn buds/horn bud tissues, and so cause much less collateral damage to surrounding tissues, as compared with some conventional dehorning techniques. [0207] These chemical disbudding agents provide a pain-relieving effect, thereby negating the need for further post-operative pain relief. [0208] Unlike eugenol, these chemical disbudding agents do not produce swelling at the site of injection. [0209] Unlike eugenol, these chemical disbudding agents do not produce open wounds nor scars at the site of injection, thereby reducing the chance of infection. [0210] Example 2 – Low viscosity, injectable solutions, suspensions and gel formulations: SAIB + NSAID cytotoxic agent [0211] It is believed that a composition providing prolonged release of the cytotoxic agent from the injection site may provide equal or superior disbudding results. It is believed that a lower amount of cytotoxic agent could be used in an injectable prolonged release composition as compared to the ones tested. Also, it is believed that since the composition provides prolonged release of the NSAID, a high dose of NSAID could also be administered safely. [0212] It is envisaged that the administered composition could be in the form of a solution or suspension in oil, or an aqueous solution or suspension, or in a low viscosity, injectable formulation (solution or suspension) which gels rapidly at the injection site to retain the cytotoxic agent for a suitable (therapeutically effective) period of time. In this way, a comparatively larger quantity of cytotoxic agent can be delivered to the horn bud cells (horn bud tissue) rather than lost to other parts of the body. [0213] It is believed that a composition containing the NSAID cytotoxic agent and a carrier oil, such as a vegetable oil, could achieve this. The composition can be formulated as an oily solution or suspension, and may provide more prolonged release of the cytotoxic agent from the injection site than a comparable solution. The solution or suspension can retain the NSAID cytotoxic agent at the horn bud cells for a period of time, rather than the cytotoxic agent being cleared rapidly from the horn bud site. [0214] It is believed that a composition containing the NSAID cytotoxic agent and an aqueous solvent could achieve this. The composition can be formulated as an aqueous solution or suspension, and may provide more prolonged release of the cytotoxic agent from the injection site than a comparable solution. [0215] It is believed that a composition containing the NSAID cytotoxic agent, Sucrose Acetate Isobutyrate (SAIB) and a solvent/s could achieve this. Once the composition containing SAIB formulation and solvent is injected, the solvent can diffuse out leaving a matrix that is both adhesive and viscous. The matrix can retain the NSAID cytotoxic agent at the horn bud cells for a period of time, rather than the cytotoxic agent being cleared rapidly from the horn bud site. [0216] Preferred NSAID cytotoxic agent + SAIB formulations are described below. [0217] Ingredient ranges [0218] Although the solvents triacetin, Transcutol™ (diethylene glycol monoethyl ether) and ethanol are exemplified below, other solvents may be used instead or in addition to these. The inventors have generally worked on the principles that they will need 40-80% SAIB and ethanol, up to 30% to adjust the release rate of the cytotoxic agent. [0219] Table 6: Cytotoxic agent meloxicam (lower dose than trialled) + SAIB formulation ingredient ranges [0220] **Low dose meloxicam is exemplified (lower than trialled), due to prolonged release from the SAIB gel. The amount of meloxicam, however, may be increased or decreased to account for a safe dose to be administered to the animal, which may also be dependent on the release rate from the SAIB gel. [0221] *Mass of ethanol to vary from 0 to 0.3 g, ie.0-30% w/v. In the absence of other solvents and Tween, and at a SAIB level of 0.8 g (80% w/v), and assuming a weight per milliliter of 1.1g for the formulation, the ethanol would be 0.29 g (29% w/v). [0222] One mL would be administered to the animal. [0223] Table 7: Preferred cytotoxic agent meloxicam (lower dose than trialed) + SAIB formulation [0224] **Low dose meloxicam is exemplified (lower than trialled), due to prolonged release from the SAIB gel. The amount of meloxicam, however, may be increased or decreased to account for a safe dose to be administered to the animal. [0225] *Assuming a weight per milliliter of 1.1g for the formulation, the mass of ethanol required is 0.23 g or 23% w/v, which should be suitable for injection. [0226] One mL would be administered to the animal. [0227] Table 8: Cytotoxic agent meloxicam (dose as trialled) + SAIB formulation ingredient ranges ^{a o up o} _{.5 m} [0228] *Mass of ethanol may vary from 0 to 0.45 g, ie.0-30% w/v, and in the absence of other solvents and Tween and at a SAIB level of 1.2 g (80%), assuming a weight per milliliter of the formulation of 1.1 g, the ethanol would be 0.43 g (28.7%). Ethanol up to 1.5 mL is to show that total volume may be increased. Ideally, the total volume would be kept at 1 mL or less but as the mass of cytotoxic agent increases, the total mass may need to be increased to 1.5 mL. This may not be the case for a small mass of cytotoxic agent, ie.20 mg, but at a 250 mg or 350 mg dose a larger total mass may be required. [0229] **Meloxicam is exemplified, with the dose as actually trialled. The amount of meloxicam, however, may be increased or decreased to account for a safe dose to be administered to the animal, which may also be dependent on the release rate from the SAIB gel. [0230] Up to 1.5 mL would be administered to the animal. [0231] Table 9: Preferred cytotoxic agent meloxicam (dose as trialled) + SAIB formulation ^{a o up o} _{.5 m} ^{e. .} [0232] **Meloxicam is exemplified, with the dose as actually trialled. The amount of meloxicam, however, may be increased or decreased to account for a safe dose to be administered to the animal. [0233] *Assuming a weight per mL of 1.1 g, the mass of ethanol required is 0.34 g or 22.7% w/v. [0234] Up to 1.5 mL would be administered to the animal. [0235] Table 10: Cytotoxic agent meloxicam (high dose range) or ketoprofen (range including as trialled low and high dose) + SAIB formulation ingredient ranges Tween 80 0-0.02 0-2 [0236] **Ketoprofen and meloxicam are exemplified. The amount of meloxicam or ketoprofen, however, may be increased or decreased to account for a safe dose to be administered to the animal, which may also be dependent on the release rate from the SAIB gel. [0237] *Mass of ethanol may vary from 0 to 0.3 g, ie. 0-30% w/v, and in the absence of other solvents and Tween and at a SAIB level of 0.7 g (70% w/v), maximum cytotoxic agent amount of 0.35 g, and a weight per mL of 1.1 g, the ethanol would be 0.05 g (5% w/v), which may be too low, in which case the maximum concentration of SAIB would have to be reduced. At least approximately 10% w/v ethanol is usually required for an injectable solution. [0238] Table 11: Cytotoxic agent meloxicam (high dose) or ketoprofen (high dose) + SAIB formulation ingredient ranges [0239] **Ketoprofen and meloxicam are exemplified. The amount of meloxicam or ketoprofen, however, may be increased or decreased to account for a safe dose to be administered to the animal, which may also be dependent on the release rate from the SAIB gel. [0240] *Mass of ethanol may vary from 0 to 0.3 g, ie. 0-30% w/v, and in the absence of other solvents and Tween and at a SAIB level of 0.7 g (70% w/v), and assuming a weight per mL of 1.1g, the ethanol would be 0.05 g (5% w/v), which may be too low, in which case the maximum concentration of SAIB would have to be reduced. At least approximately 10% w/v ethanol is usually required for an injectable formulation. [0241] Table 12: Cytotoxic agent meloxicam (high dose) or ketoprofen (as trialled) + SAIB formulation ingredient ranges [0242] **Ketoprofen and meloxicam are exemplified. The amount of meloxicam or ketoprofen, however, may be increased or decreased to account for a safe dose to be administered to the animal, which may also be dependent on the release rate from the SAIB gel. [0243] *Mass of ethanol may vary from 0 to 0.45 g, ie.0-30% w/v, and in the absence of other solvents and Tween and at a SAIB level of 1.2 g (80%), and assuming a weight per mL of 1.1 g, the ethanol would be 0.3 g (20% w/v). [0244] Up to 1.5 mL would be administered to the animal. [0245] Table 13: Cytotoxic agent ketoprofen (high dose) + SAIB formulation [0246] **Ketoprofen is exemplified. The amount of ketoprofen, however, may be increased or decreased to account for a safe dose to be administered to the animal. [0247] Surprisingly, the inventors have found that SAIB seems to increase the physical stability (or perhaps solubility) of ketoprofen (into a clear solution) in ethanol. [0248] Table 14: Cytotoxic agent ketoprofen (as trailed) + SAIB formulation [0249] **Ketoprofen is exemplified. The amount of ketoprofen, however, may be increased or decreased. [0250] *Assuming a weight per mL of 1.1 g, this will contain 19% w/v ethanol. [0251] Table 15: Preferred cytotoxic agent ketoprofen (low dose) + SAIB formulation [0252] **Low dose ketoprofen is exemplified, due to prolonged release from the SAIB gel. The amount of ketoprofen, however, may be increased or decreased. [0253] *Assuming a weight per mL of 1.1g, this will contain 17% w/v ethanol. [0254] Note, all estimates of the % w/v ethanol have assumed a weight per mL of the formulation of 1.1 g. The actual values will vary, for example, as the SAIB content is reduced the weight per mL is likely to be lower. Actual values would be determined experimentally using well-known methods. [0255] Aspects of the present invention have been described by way of example only and it should be appreciated that modifications and additions may be made thereto without departing from the scope thereof as defined in the appended claims. [0256] All references, including any patents or patent applications cited in this specification are hereby incorporated by reference. No admission is made that any reference constitutes prior art. It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents form part of the common general knowledge in the art in any country. [0257] Throughout this specification, the word "comprise", or variations thereof such as "comprises" or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. [0258] Context permitting, the term ‘approximately’ or ‘about’ generally means up to 10%, plus or minus, of the referenced number, but this need not be the case.